48
Views
0
CrossRef citations to date
0
Altmetric
Letter

Incorrect description of mode of excretion of linagliptin

&
Page 93 | Published online: 02 Jun 2010

References

  • CoxMERowellJCorsinoLGreenJBDipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacyDrug, Healthcare and Patient Safety20102719
  • HeiseTGraefe-ModyEUHüttnerSRingATrommeshauserDDugiKAPharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patientsDiabetes Obes Metab200911878679419476474